Skip to main content

News from NCI about COVID-19

NCI is adapting to the extraordinary circumstances imposed on the cancer community by COVID-19. The institute has taken measures to help meet patients’ needs and to keep the nation’s cancer research enterprise operating to the fullest extent possible.

  • Cancer Research in the Era of COVID-19

    In this NCI Bottom Line blog post, NCI Deputy Director Dinah Singer, Ph.D., highlights examples of how NCI continues to make progress in cancer research during the era of COVID-19 and provides details on how NCI, working with NIH, has implemented new flexibilities for the cancer research community during this crisis.

  • NCI Part of Federal Effort to Evaluate Antibody Tests for Novel Coronavirus

    NCI scientists, along with experts from other government agencies and academic medical centers, have launched a joint effort to help FDA evaluate commercially available antibody tests for SARS-CoV-2, the coronavirus that causes COVID-19.

  • At NCI, A Robust and Rapid Response to the COVID-19 Pandemic

    NCI is lending its tremendous expertise and unique research capabilities to the global response to the COVID-19 pandemic. NCI Director Dr. Norman Sharpless describes some of the COVID-19 specific research activities NCI has initiated.

  • Cancer Research Training in the Era of COVID-19

    The director of NCI’s Center for Cancer Training, Dr. Oliver Bogler, addresses grantees about cancer research training during this unprecedented time. He advises the cancer research community to follow NIH/NCI grants guidance and suggests ideas for how grantees and trainees can use their time.

  • NCI Funding during the COVID-19 Public Health Emergency

    NCI Director Dr. Norman E. Sharpless addresses the grantee community about NCI funding and operations during the COVID-19 public health emergency. Dr. Sharpless highlights NCI’s peer review schedule, our program staff, as well as general NCI grants administration processes during this time.

  • NCI statement on clinical trials during COVID-19 pandemic

    Statement from the National Cancer Institute providing information regarding treatment of cancer patients and participation in clinical trials during the COVID-19 pandemic.

Multimedia Presentations